Media OutReach
Melco launches the world’s first and Macau’s only integrated resort hospital with MRI & CT facilities
Strengthening the city’s position as a growing medical tourism hub with the opening of iRad Hospital at Studio City
MACAO SAR – Media OutReach Newswire – 6 October 2025 – Melco Resorts & Entertainment has announced the launch of the world’s first and Macau’s only integrated resort hospital with MRI & CT Scanning facilities in partnership with iRad, Hong Kong’s largest MRI diagnostic services provider. This initiative underlines Melco’s commitment to supporting the SAR government’s efforts to promoting the development of the “Big Health” sector and advancing Macau’s position as a growing medical tourism hub. The new iRad Hospital further enhances the city’s tourism infrastructure by introducing a robust medical and wellness ecosystem that strategically complements its existing world-class offerings.
Located in Melco’s Studio City, the newly-opened iRad Hospital redefines the healthcare experience by seamlessly integrating world-class health screening, diagnostic imaging, aesthetic medicine, longevity treatments, and medical concierge services. This revolutionary healthcare concept pioneers a new era of medical tourism in Macau, positioning the city as a prime destination for health, rejuvenation, and well-being.
iRad Hospital leverages the growing global demand for high-quality medical services and continued rise in the number of tourists visiting Macau. By offering cutting-edge medical tourism experiences, the hospital aims to attract regional and overseas visitors, encouraging longer stays longer and higher spending at both Studio City and in Macau, while attracting repeat and long term guests through providing top-tier medical tourism experiences.
A grand opening event was hosted at iRad Hospital in Studio City today, where Guests of Honor including Mr. Lo Iek Long, Director for Department of Health of the Macao SAR; Ms. Maria Helena de Senna Fernandes, Director of Macau Government Tourism Office; Mr. Che Weng Keong, Alex, President of the Commerce and Investment Promotion Institute of the Macao SAR and Mr. Sun Yaohua, Director of the Economic Affairs Department of the Liaison Office of the Central People’s Government in the Macao SAR, were welcomed by Melco Chairman & CEO, Mr. Lawrence Ho, President and Board Director, Mr. Evan Winkler, Chief Advisor, Dr. Kent Wong; and iRad Hospital’s Honorary Chairman Mr. Dennis Tam; Founder & Chairman, Dr. Matthew Ngan, and CEO Mr. Kin Wong. More than 150 guests were in attendance.
Mr. Lawrence Ho, Chairman & CEO, Melco Resorts & Entertainment, said, “By launching the world’s first and Macau’s only hospital with MRI & CT facilities within an integrated resort, we strive to contribute to the advancement of medical tourism in Macau. This project aligns with the SAR government’s ‘1+4’ economic diversification strategy, and we are thankful for the government’s support and guidance throughout the development process.
“Our goal is to provide guests with world-class, integrated entertainment and health options. With its existing array of world-class entertainment offerings, Melco’s Studio City is now set to become a leading destination for health and wellness, establishing Macau as the region’s foremost medical and wellness tourism hub whilst reinforcing the local economy and creating invaluable job opportunities for the community.”
Mr. Dennis Tam, Honorary Chairman of iRad, said, “We are privileged, together with our partner Melco, to announce our first medical project in Macau, marking a significant contribution to supporting the Macau government’s initiative of positioning the city as a state-level regional medical hub.
“As the leading private-sector diagnostics medical group in Hong Kong, we are confident that this health and wellness project will establish a new benchmark for medical excellence in Macau, attracting patients and visitors from across the region.
“At iRad, we are proud to introduce the first and largest hospital in the world to feature both MRI and CT scan equipment within an integrated resort.
“With its large and growing tourism sector, projected to welcome 38–39 million visitors annually, Macau offers an unparalleled opportunity to become the leading regional medical tourism destination.”
The iRad Hospital at Studio City represents a landmark achievement in Macau’s journey to becoming a global leader in medical tourism, offering an unparalleled fusion of healthcare, wellness, and entertainment under one roof.
About iRad – Hong Kong’s largest MRI diagnostic services provider
Established in 2006, iRad is a trusted leader in diagnostic radiology across Hong Kong. As at 2024, iRad was the largest MRI diagnostic services provider in Hong Kong by revenue and by the number of MRI scanners. Focused on delivering high-quality imaging services and exceptional patient care, the Group’s strong and extensive client base includes the Government of the Hong Kong SAR, as well as other high-profile medical groups, corporations, private doctors and NGOs. Meanwhile, iRad Hopspital is the first and largest private medical imaging and examination service provider within an integrated resort in Macau, making iRad Group the first medical imaging group in the world to offer comprehensive private imaging and examination services, including MRI and CT services, to the integrated resort industry.
Hashtag: #melco #studiocity #iRad #iRadHospital
https://www.melco-resorts.com
https://linkedin.com/company/melco-resorts-entertainment
https://x.com/melcoresorts
https://www.facebook.com/MelcoCSR/
Wechat: 新濠博亚娱乐
The issuer is solely responsible for the content of this announcement.
About Melco Resorts & Entertainment Limited
The Company, with its American depositary shares listed on the Nasdaq Global Select Market (Nasdaq: MLCO), is a developer, owner and operator of integrated resort facilities in Asia and Europe. The Company currently operates City of Dreams (www.cityofdreamsmacau.com) and Altira Macau (www.altiramacau.com), integrated resorts located in Cotai and Taipa, Macau, respectively. In addition, the Company operates Studio City (www.studiocity-macau.com), a cinematically-themed integrated resort in Cotai, Macau. In the Philippines, the Company operates and manages City of Dreams Manila (www.cityofdreamsmanila.com), an integrated resort in the Entertainment City complex in Manila. In South Asia, the Company manages the Nüwa Sri Lanka hotel at City of Dreams Sri Lanka, an integrated resort in Colombo, Sri Lanka. In Europe, the Company operates City of Dreams Mediterranean, an integrated resort in Limassol, in the Republic of Cyprus (www.cityofdreamsmed.com.cy). For more information about the Company, please visit www.melco-resorts.com.
The Company is majority owned by Melco International Development Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited, which is in turn majority owned and led by Mr. Lawrence Ho, who is the Chairman, Executive Director and Chief Executive Officer of the Company.
Through DaaS, enterprise customers can access drone equipment, trained personnel, mission execution, data collection and project deliverables without purchasing and maintaining a complete in-house drone system. The model extends ZenaTech’s business beyond equipment sales and enables the company to generate recurring service revenue from customers’ operational requirements.
ZenaTech reported revenue of CAD 8.4 million for the first quarter of 2026, an increase of 640% from CAD 1.13 million in the same period of 2025. DaaS contributed approximately CAD 7.8 million, accounting for around 93% of quarterly revenue.
In 2025, the company generated annual revenue of CAD 12.9 million, up 558% from approximately CAD 2 million in 2024. DaaS contributed approximately CAD 10.1 million during its first full year of operations, representing around 78% of total annual revenue.
Acquisitions Support Service Network Expansion
ZenaTech has expanded its DaaS operations through a combination of internal technology development and acquisitions. The acquired businesses bring existing customers, professional teams and local operating capabilities, while ZenaTech gradually introduces drones, automated data collection and AI-supported analytics into selected workflows.
In 2025, the company completed 20 acquisitions, including 19 businesses providing engineering data, facility inspection and related professional services, as well as one enterprise software company.
By June 2026, ZenaTech had completed its 24th DaaS-related acquisition and expanded its services into property cleaning, facility inspection and maintenance.
Through its ZenaDrone subsidiary, ZenaTech has also developed drone products for indoor and outdoor operations. The IQ Quad supports site data collection, engineering imagery and 3D modelling, while the IQ Nano uses barcode and RFID scanning to support inventory records, shelf inspections and indoor data collection.
The company’s reported revenue growth, acquisition activity and DaaS contribution provide investors following the AI and drone sectors with measurable indicators of how its technologies are being integrated into commercial operations and converted into service revenue.
Hashtag: #ZenaTech
The issuer is solely responsible for the content of this announcement.
About ZenaTech
ZenaTech (Nasdaq: ZENA) is a technology company specialising in AI-powered drones, Drone-as-a-Service (DaaS), enterprise SaaS solutions and related technologies. Through its ZenaDrone subsidiary, the company develops drone products and software for commercial applications including engineering data collection, agriculture, warehouse management, facility inspection and property maintenance. ZenaTech combines its technology capabilities with a growing professional service network to support the adoption of drone-based solutions across a range of operational environments.
Media OutReach
A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation
The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in detecting cancers within the scope of the assay. These include five common cancers — breast, lung, liver, colorectal and gastric cancers — and five aggressive, less common cancers that currently lack standard screening methods — ovarian, pancreatic, esophageal, endometrial and head & neck cancers.
SPOT-MAS has been developed through years of rigorous scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer screening blood test in Asia to complete a large prospective cohort validation, with the K-DETEK study evaluating more than 9,000 asymptomatic participants and demonstrating strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.
Since then, SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and were featured at ASCO Breakthrough 2026 in Singapore.
The platform is built on a multi-omic approach— integrating genetics, epigenetics, and fragmentomics — together with AI-driven analysis, large-scale prospective validation, growing real-world evidence and focus on cancer types with high clinical relevance in the regions where the test is deployed.
For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans.
Looking ahead, Gene Solutions will continue to collaborate with academic, clinical, laboratory, commercial and strategic partners to support responsible adoption of SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.
Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.
For more information, visit https://spotmas.com.hk
Contact:
hk***@***********ns.com
Source: Gene Solutions Hong Kong Limited.
SPOTMAS_062026_04
Hashtag: #SPOTMAS
https://spotmas.com.hk/The issuer is solely responsible for the content of this announcement.
Media OutReach
St Francis Methodist School International Shares 2023–2024 WACE Outcomes and Student Journeys
Overview of the WACE Curriculum at SFMS
SFMS International is among a small number of institutions in Singapore offering the WACE curriculum and has delivered this programme for over 23 years. The WACE is a recognised senior secondary qualification awarded by the School Curriculum and Standards Authority (SCSA) on behalf of the Ministry of Education, Western Australia. It prepares students for university admission both locally and internationally.
SFMS is also currently the only school in Singapore offering a Senior High Preparatory Pathway (WACE) for students in Years 9–10. This introduces students to the structure and expectations of the curriculum earlier, building familiarity with subject content and assessment formats before progressing to the senior years. Additionally, subject selection in Years 11A and 12A is structured to meet university entry requirements and reflect students’ academic interests.
Academic Outcomes and University Placements
In 2023, 8 out of 12 WACE graduates from SFMS International achieved ATAR scores above 90, meeting the eligibility criteria for universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU). The cohort’s top scorer, Wang Dawei, recorded an ATAR of 96.15 and enrolled at NTU to study Business and International Trading. In addition to local placements, graduates were admitted to international universities such as the University of Melbourne and Fudan University in China.
In 2024, 2 out of 8 graduates also attained ATAR scores above 90. The highest scorer, Youn Chae-Won, achieved an ATAR of 95.3. Her university placement is currently pending.
Student Journeys and Holistic Development
Students in the WACE programme at SFMS International engage in both academic and co-curricular activities as part of their overall learning experience. Recent graduates have taken part in service learning, subject specialisation, and personal reflection throughout their time in the pre-university programme.
Youn Chae-Won, the 2024 valedictorian, joined SFMS International from Korea in 2021. Over time, she adjusted to a new academic environment and explored subjects such as accounting, which influenced her interest in finance-related pathways. She also took part in various aspects of school life, including a service learning trip to Bintan in 2023, where students supported local sanitation efforts. Her involvement in both academic and co-curricular settings marked a broad engagement with school life during her time at SFMS.
Andrew Zhuang, who enrolled in SFMS International in 2019, pursued subjects such as Business Management, Accounting, and English as an Additional Language (EALD). Beyond academics, he was involved in community fundraising and joined the same Bintan service trip. He also attended weekly chapel sessions and received support from peers and teachers during a period of health-related absence.
These outcomes reflect the ongoing role of the WACE programme at SFMS International in supporting students through both academic pathways and broader educational experiences. Under the leadership of Principal Mr Lee Hak Boon, the school continues to emphasise academic planning, subject selection, and student wellbeing as part of its overall approach to pre-university education.
Hashtag: #StFrancisMethodistSchoolInternational
https://www.sfms.edu.sg/
https://www.facebook.com/sfms.singapore
https://www.instagram.com/sfms_sg/
https://www.youtube.com/channel/UC_bb9hcNhAk7WgYBE_FI61A/featured
The issuer is solely responsible for the content of this announcement.
About St Francis Methodist School International
Established in 1960, St Francis Methodist School International (SFMS) is an educational institution in Singapore that offers primary, secondary, and pre-university programmes. The school provides several academic pathways, including the International Baccalaureate (IB), Cambridge IGCSE, and the Western Australian Certificate of Education (WACE), preparing students for further studies in local and overseas institutions.
